Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study.

Cox DA, Wang H, Nicolay C, Bethel MA

Diabetes, obesity & metabolism29 May 2022Cited by 4 (Europe PMC)

PMID35546790PMCIDPMC9543252DOI10.1111/dom.14762PepBankPUB-35546790

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialEfficacy outcome
In high Framingham risk and REWIND-like diabetes groups, dulaglutide produced dose-related total cholesterol decreases of ≤6.0%.
In plain wordsIn higher-risk diabetes groups, total cholesterol decreased with dulaglutide compared with baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseTotal cholesterol
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Studied dose
1.5, 3.0 or 4.5 mg once weekly · 52 weeksAs given in this study (human).
Measurements
Total cholesterol change
≤ 6%
high Framingham risk and REWIND-like groups
Source sentences
Summary
In the high Framingham CVD risk and REWIND-like groups, dulaglutide resulted in dose-related decreases in total cholesterol (≤6.0%)
2 context sentences(design, population, supporting numbers)
Summary · context
Participants who received once weekly dulaglutide 1.5, 3.0 or 4.5 mg for 52 weeks were categorized according to their baseline Framingham CVD risk category [low (N = 295), medium (N = 481) and high (N = 1054) risk], as well as their baseline CVD risk according to the REWIND study eligibility criteria (N = 953).
Summary · context
Data were analysed as least squares mean percentage change from baseline for lipids and least squares mean change from baseline for vital signs.
Report a problemFND-3554679001
02HumanNon-randomized trialEfficacy outcome
In high Framingham risk and REWIND-like diabetes groups, dulaglutide produced dose-related non-high-density lipoprotein cholesterol decreases of ≤8.8%.
In plain wordsIn higher-risk diabetes groups, non-HDL cholesterol decreased with dulaglutide compared with baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseNon-HDL cholesterol
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Studied dose
1.5, 3.0 or 4.5 mg once weekly · 52 weeksAs given in this study (human).
Measurements
Non-HDL cholesterol change
≤ 8.8%
high Framingham risk and REWIND-like groups
Source sentences
Summary
In the high Framingham CVD risk and REWIND-like groups, dulaglutide resulted in dose-related decreases in total cholesterol (≤6.0%), non-high-density lipoprotein cholesterol (≤8.8%)
2 context sentences(design, population, supporting numbers)
Summary · context
Participants who received once weekly dulaglutide 1.5, 3.0 or 4.5 mg for 52 weeks were categorized according to their baseline Framingham CVD risk category [low (N = 295), medium (N = 481) and high (N = 1054) risk], as well as their baseline CVD risk according to the REWIND study eligibility criteria (N = 953).
Summary · context
Data were analysed as least squares mean percentage change from baseline for lipids and least squares mean change from baseline for vital signs.
Report a problemFND-3554679002
03HumanNon-randomized trialEfficacy outcome
In high Framingham risk and REWIND-like diabetes groups, dulaglutide produced dose-related very-low-density lipoprotein cholesterol decreases of ≤19.4%.
In plain wordsIn higher-risk diabetes groups, VLDL cholesterol decreased with dulaglutide compared with baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseVLDL cholesterol
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Studied dose
1.5, 3.0 or 4.5 mg once weekly · 52 weeksAs given in this study (human).
Measurements
VLDL cholesterol change
≤ 19.4%
high Framingham risk and REWIND-like groups
Source sentences
Summary
In the high Framingham CVD risk and REWIND-like groups, dulaglutide resulted in dose-related decreases in total cholesterol (≤6.0%), non-high-density lipoprotein cholesterol (≤8.8%), very-low-density lipoprotein cholesterol (≤19.4%)
2 context sentences(design, population, supporting numbers)
Summary · context
Participants who received once weekly dulaglutide 1.5, 3.0 or 4.5 mg for 52 weeks were categorized according to their baseline Framingham CVD risk category [low (N = 295), medium (N = 481) and high (N = 1054) risk], as well as their baseline CVD risk according to the REWIND study eligibility criteria (N = 953).
Summary · context
Data were analysed as least squares mean percentage change from baseline for lipids and least squares mean change from baseline for vital signs.
Report a problemFND-3554679003
04HumanNon-randomized trialEfficacy outcome
In high Framingham risk and REWIND-like diabetes groups, dulaglutide produced dose-related triglyceride decreases of ≤21.5%.
In plain wordsIn higher-risk diabetes groups, triglycerides decreased with dulaglutide compared with baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseTriglycerides
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Studied dose
1.5, 3.0 or 4.5 mg once weekly · 52 weeksAs given in this study (human).
Measurements
Triglyceride change
≤ 21.5%
high Framingham risk and REWIND-like groups
Source sentences
Summary
In the high Framingham CVD risk and REWIND-like groups, dulaglutide resulted in dose-related decreases in total cholesterol (≤6.0%), non-high-density lipoprotein cholesterol (≤8.8%), very-low-density lipoprotein cholesterol (≤19.4%) and triglycerides (≤21.5%)
2 context sentences(design, population, supporting numbers)
Summary · context
Participants who received once weekly dulaglutide 1.5, 3.0 or 4.5 mg for 52 weeks were categorized according to their baseline Framingham CVD risk category [low (N = 295), medium (N = 481) and high (N = 1054) risk], as well as their baseline CVD risk according to the REWIND study eligibility criteria (N = 953).
Summary · context
Data were analysed as least squares mean percentage change from baseline for lipids and least squares mean change from baseline for vital signs.
Report a problemFND-3554679004
05HumanNon-randomized trialEfficacy outcome
In high Framingham risk and REWIND-like diabetes groups, LDL cholesterol changed little during dulaglutide treatment.
In plain wordsIn higher-risk diabetes groups, LDL cholesterol changed little with dulaglutide compared with baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedLDL cholesterol
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Studied dose
1.5, 3.0 or 4.5 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
with little change in low-density lipoprotein cholesterol and high-density lipoprotein cholesterol.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants who received once weekly dulaglutide 1.5, 3.0 or 4.5 mg for 52 weeks were categorized according to their baseline Framingham CVD risk category [low (N = 295), medium (N = 481) and high (N = 1054) risk], as well as their baseline CVD risk according to the REWIND study eligibility criteria (N = 953).
Summary · context
Data were analysed as least squares mean percentage change from baseline for lipids and least squares mean change from baseline for vital signs.
Report a problemFND-3554679005
06HumanNon-randomized trialEfficacy outcome
In high Framingham risk and REWIND-like diabetes groups, HDL cholesterol changed little during dulaglutide treatment.
In plain wordsIn higher-risk diabetes groups, HDL cholesterol changed little with dulaglutide compared with baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedHDL cholesterol
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Studied dose
1.5, 3.0 or 4.5 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
with little change in low-density lipoprotein cholesterol and high-density lipoprotein cholesterol.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants who received once weekly dulaglutide 1.5, 3.0 or 4.5 mg for 52 weeks were categorized according to their baseline Framingham CVD risk category [low (N = 295), medium (N = 481) and high (N = 1054) risk], as well as their baseline CVD risk according to the REWIND study eligibility criteria (N = 953).
Summary · context
Data were analysed as least squares mean percentage change from baseline for lipids and least squares mean change from baseline for vital signs.
Report a problemFND-3554679006
07HumanNon-randomized trialEfficacy outcome
In AWARD-11 cardiovascular risk analyses, systolic blood pressure decreased up to 5.6 mmHg during dulaglutide treatment.
In plain wordsSystolic blood pressure decreased during dulaglutide treatment compared with baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseSystolic blood pressure
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
1.5, 3.0 or 4.5 mg once weekly · 52 weeksAs given in this study (human).
Measurements
Systolic blood pressure decrease
≤ 5.6 mmHg
dulaglutide
Source sentences
Summary
Systolic and diastolic blood pressure decreased up to 5.6 mmHg and 1.6 mmHg, respectively, and heart rate increased up to 2 beats/min.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants who received once weekly dulaglutide 1.5, 3.0 or 4.5 mg for 52 weeks were categorized according to their baseline Framingham CVD risk category [low (N = 295), medium (N = 481) and high (N = 1054) risk], as well as their baseline CVD risk according to the REWIND study eligibility criteria (N = 953).
Summary · context
Data were analysed as least squares mean percentage change from baseline for lipids and least squares mean change from baseline for vital signs.
Report a problemFND-3554679007
08HumanNon-randomized trialEfficacy outcome
In AWARD-11 cardiovascular risk analyses, diastolic blood pressure decreased up to 1.6 mmHg during dulaglutide treatment.
In plain wordsDiastolic blood pressure decreased during dulaglutide treatment compared with baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseDiastolic blood pressure
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
1.5, 3.0 or 4.5 mg once weekly · 52 weeksAs given in this study (human).
Measurements
Diastolic blood pressure decrease
≤ 1.6 mmHg
dulaglutide
Source sentences
Summary
Systolic and diastolic blood pressure decreased up to 5.6 mmHg and 1.6 mmHg, respectively, and heart rate increased up to 2 beats/min.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants who received once weekly dulaglutide 1.5, 3.0 or 4.5 mg for 52 weeks were categorized according to their baseline Framingham CVD risk category [low (N = 295), medium (N = 481) and high (N = 1054) risk], as well as their baseline CVD risk according to the REWIND study eligibility criteria (N = 953).
Summary · context
Data were analysed as least squares mean percentage change from baseline for lipids and least squares mean change from baseline for vital signs.
Report a problemFND-3554679008
09HumanNon-randomized trialSafety outcome
In AWARD-11 cardiovascular risk analyses, heart rate increased up to 2 beats/min during dulaglutide treatment.
In plain wordsHeart rate increased during dulaglutide treatment compared with baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseHeart rate
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
1.5, 3.0 or 4.5 mg once weekly · 52 weeksAs given in this study (human).
Measurements
Heart rate increase
≤ 2 beats/min
dulaglutide
Source sentences
Summary
Systolic and diastolic blood pressure decreased up to 5.6 mmHg and 1.6 mmHg, respectively, and heart rate increased up to 2 beats/min.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants who received once weekly dulaglutide 1.5, 3.0 or 4.5 mg for 52 weeks were categorized according to their baseline Framingham CVD risk category [low (N = 295), medium (N = 481) and high (N = 1054) risk], as well as their baseline CVD risk according to the REWIND study eligibility criteria (N = 953).
Summary · context
Data were analysed as least squares mean percentage change from baseline for lipids and least squares mean change from baseline for vital signs.
Report a problemFND-3554679009

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT03495102

A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

Eli Lilly and Companyn = 1,8425 Apr 2018 to 10 Oct 2019

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 12 Jun 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.